BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

585 related articles for article (PubMed ID: 20208060)

  • 1. The risk of post-molar gestational trophoblastic neoplasia is higher in heterozygous than in homozygous complete hydatidiform moles.
    Baasanjav B; Usui H; Kihara M; Kaku H; Nakada E; Tate S; Mitsuhashi A; Matsui H; Shozu M
    Hum Reprod; 2010 May; 25(5):1183-91. PubMed ID: 20208060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Malignant potential of homozygous and heterozygous complete moles.
    Wake N; Seki T; Fujita H; Okubo H; Sakai K; Okuyama K; Hayashi H; Shiina Y; Sato H; Kuroda M
    Cancer Res; 1984 Mar; 44(3):1226-30. PubMed ID: 6318983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gestational Trophoblastic Neoplasia From Genetically Confirmed Hydatidiform Moles: Prospective Observational Cohort Study.
    Usui H; Qu J; Sato A; Pan Z; Mitsuhashi A; Matsui H; Shozu M
    Int J Gynecol Cancer; 2018 Nov; 28(9):1772-1780. PubMed ID: 30358702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The propensity to malignancy of dispermic, heterozygous moles].
    Hashimoto M
    Hokkaido Igaku Zasshi; 1987 Jul; 62(4):564-72. PubMed ID: 2960601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of gestational trophoblastic neoplasia after hCG normalisation according to hydatidiform mole type.
    Schmitt C; Doret M; Massardier J; Hajri T; Schott AM; Raudrant D; Golfier F
    Gynecol Oncol; 2013 Jul; 130(1):86-9. PubMed ID: 23523617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical features of multiple conception with partial or complete molar pregnancy and coexisting fetuses.
    Steller MA; Genest DR; Bernstein MR; Lage JM; Goldstein DP; Berkowitz RS
    J Reprod Med; 1994 Mar; 39(3):147-54. PubMed ID: 8035369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterozygous/dispermic complete mole confers a significantly higher risk for post-molar gestational trophoblastic disease.
    Zheng XZ; Qin XY; Chen SW; Wang P; Zhan Y; Zhong PP; Buza N; Jin YL; Wu BQ; Hui P
    Mod Pathol; 2020 Oct; 33(10):1979-1988. PubMed ID: 32404958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of Her-2/neu expression in hydatidiform moles for prediction of subsequent gestational trophoblastic neoplasia.
    Menczer J; Schreiber L; Berger E; Golan A; Levy T
    Gynecol Oncol; 2007 Mar; 104(3):675-9. PubMed ID: 17126893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postevacuation hCG levels and risk of gestational trophoblastic neoplasia in women with complete molar pregnancy.
    Wolfberg AJ; Berkowitz RS; Goldstein DP; Feltmate C; Lieberman E
    Obstet Gynecol; 2005 Sep; 106(3):548-52. PubMed ID: 16135585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of postmolar gestational trophoblastic disease in androgenetic moles and the morphological features associated with low risk postmolar gestational trophoblastic disease.
    Kaneki E; Kobayashi H; Hirakawa T; Matsuda T; Kato H; Wake N
    Cancer Sci; 2010 Jul; 101(7):1717-21. PubMed ID: 20518791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of recurrent hydatidiform mole and subsequent pregnancy outcome following complete or partial hydatidiform molar pregnancy.
    Sebire NJ; Fisher RA; Foskett M; Rees H; Seckl MJ; Newlands ES
    BJOG; 2003 Jan; 110(1):22-6. PubMed ID: 12504931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormonal contraceptive use before hCG remission does not increase the risk of gestational trophoblastic neoplasia following complete hydatidiform mole: a historical database review.
    Braga A; Maestá I; Short D; Savage P; Harvey R; Seckl MJ
    BJOG; 2016 Jul; 123(8):1330-5. PubMed ID: 26444183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete hydatidiform mole with retained maternal chromosomes 6 and 11.
    McConnell TG; Norris-Kirby A; Hagenkord JM; Ronnett BM; Murphy KM
    Am J Surg Pathol; 2009 Sep; 33(9):1409-15. PubMed ID: 19542869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gestational trophoblastic neoplasia after spontaneous human chorionic gonadotropin normalization following molar pregnancy evacuation.
    Braga A; Maestá I; Matos M; Elias KM; Rizzo J; Viggiano MG
    Gynecol Oncol; 2015 Nov; 139(2):283-7. PubMed ID: 26383828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Invasive Complete Hydatidiform Moles: Analysis of a Case Series With Genotyping.
    Bynum J; Murphy KM; DeScipio C; Beierl K; Adams E; Anderson D; Vang R; Ronnett BM
    Int J Gynecol Pathol; 2016 Mar; 35(2):134-41. PubMed ID: 26535984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Twin pregnancy consisting of 46, XY heterozygous complete mole coexisting with a live fetus.
    Kashimura Y; Tanaka M; Harada N; Shinmoto M; Morishita T; Morishita H; Kashimura M
    Placenta; 2001 Apr; 22(4):323-7. PubMed ID: 11286568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical characteristics of persistent gestational trophoblastic neoplasia after partial hydatidiform molar pregnancy.
    Feltmate CM; Growdon WB; Wolfberg AJ; Goldstein DP; Genest DR; Chinchilla ME; Lieberman ES; Berkowitz RS
    J Reprod Med; 2006 Nov; 51(11):902-6. PubMed ID: 17165438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA Genotyping of Nonmolar Donor Egg Pregnancies With Abnormal Villous Morphology: Allele Zygosity Patterns Prevent Misinterpretation as Complete Hydatidiform Mole.
    Joseph NM; Pineda C; Rabban JT
    Int J Gynecol Pathol; 2018 Mar; 37(2):191-197. PubMed ID: 28463912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic characteristics and subsequent pregnancy outcome in 139 complete hydatidiform moles.
    Horn LC; Kowalzik J; Bilek K; Richter CE; Einenkel J
    Eur J Obstet Gynecol Reprod Biol; 2006; 128(1-2):10-4. PubMed ID: 16530318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current management of gestational trophoblastic diseases.
    Berkowitz RS; Goldstein DP
    Gynecol Oncol; 2009 Mar; 112(3):654-62. PubMed ID: 18851873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.